A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
Latest Information Update: 09 May 2025
At a glance
- Drugs Tuvusertib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 04 May 2025 Planned End Date changed from 29 May 2025 to 18 Jun 2026.
- 04 May 2025 Planned primary completion date changed from 29 May 2025 to 18 Jun 2026.
- 01 May 2025 Planned End Date changed from 25 Apr 2025 to 29 May 2025.